← Leaderboards
Stanley H. Appel
Baylor College Of Medicine
$2,156,682
Attributed
$2,156,682
Total exposure
6
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $300.7K · FY2005–14$500K$375K$250K$125K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
Funding mix
By agency
NIH$2,756,682 · 7
By mechanism
R01$1,190,766 · 1
R21$854,263 · 2
P50$679,625 · 2
M01$32,028 · 2
Top collaborators
No co-investigators on record.
Most similar at Baylor College Of Medicine
Same institution · by research overlap
- Pragna Patel$3,346,344
- Timothy Edward Lotze$20,665
- Diana Cox$134,580
- Aladin Mohamed Boriek$5,602,934
- Christine Beeton$7,582,844
Others in their field
Top investigators on “Amyotrophic Lateral Sclerosis”
- Merit E Cudkowicz · Massachusetts General Hospital$54,029,758
- James Dale Berry · Brigham And Women'S Hospital$37,291,450
- Sabrina Paganoni · Massachusetts General Hospital$36,168,406
- Suma Babu · Massachusetts General Hospital$36,168,406
- Jeffrey D Rothstein · Massachusetts General Hospital$22,909,620
- Teepu Siddique · University Of Chicago$22,641,778
Research focus
Amyotrophic Lateral SclerosisMotor NeuronsCellsDisease ProgressionEffective TherapyImmune SystemPlayMutantRegulatory T-LymphocyteCytokineSuperoxide DismutaseNeurodegenerative DisordersLymph NodesCytotoxicityMediatingBloodAnimal ModelLeadMicrogliaInflammationInflammatoryCell TherapyClinical TrialsInjury
Grant awards (12)
Blocking TLR-Activation of Regulatory T cells Slows Disease in ALS$233,888
R21 · FY2014 · NS · contact PI
Blocking TLR-Activation of Regulatory T cells Slows Disease in ALS$196,875
R21 · FY2013 · NS · contact PI
Using CD4+ T cells as a candidate therapy to slow disease progression in ALS$192,500
R21 · FY2011 · NS · contact PI
CLINICAL TRIAL: PHASE I/II TRIAL USING CYCLOPHOSPHAMIDE AND LOW-DOSE IL-2 TO IN$31,265
M01 · FY2011 · RR · contact PI
Using CD4+ T cells as a candidate therapy to slow disease progression in ALS$231,000
R21 · FY2010 · NS · contact PI
CLINICAL TRIAL: PHASE I/II TRIAL USING CYCLOPHOSPHAMIDE AND LOW-DOSE IL-2 TO IND$763
M01 · FY2010 · RR · contact PI
The Role of Microglia in Models of ALS$284,170
R01 · FY2007 · NS · contact PI
The Role of Microglia in Models of ALS$292,657
R01 · FY2006 · NS · contact PI
The Role of Microglia in Models of ALS$300,711
R01 · FY2005 · NS
The Role of Microglia in Models of ALS$313,228
R01 · FY2004 · NS
ALZHEIMERS DISEASE RESEARCH CENTER$600,000
P50 · FY2000 · AG
SELECTIVE VULNERABILITY OF SPORADIC NEURODEGENERATIVE DISEASE$79,625
P50 · FY2000 · AG